NeuroTrauma Sciences

Executive Summary

NeuroTrauma Sciences is a private, Phase 1 biotechnology company headquartered in Atlanta, GA, focused on developing novel small molecule therapies for neurotrauma, including traumatic brain injury (TBI) and spinal cord injury. Founded in 2016, the company leverages deep expertise in chemistry, manufacturing, and controls (CMC) under President Scot Barry, who brings over 30 years of CDMO and biopharmaceutical experience. NeuroTrauma Sciences aims to address the significant unmet medical need in CNS injuries, where no effective pharmacotherapies currently exist. The company's lead program targets secondary injury cascades following acute neurotrauma, with the potential to improve functional recovery and reduce long-term disability. As a privately held, early-stage company, NeuroTrauma Sciences has not disclosed specific financial details or pipeline assets publicly. However, its focus on small molecules and strategic CMC development positions it for efficient manufacturing scalability. The company's stage suggests it is likely advancing a lead candidate toward or through Phase 1 clinical trials. Success in early development could attract larger pharmaceutical partners or additional funding for pivotal studies. Key risks include the inherent challenges of CNS drug development, regulatory hurdles, and competition from other neurotrauma-focused biotechs. Nonetheless, the specialized focus and experienced management team provide a foundation for potential value creation in a high-need area.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead candidate60% success
• Q1 2027Strategic partnership or licensing deal for CNS platform40% success
• Q2 2027IND filing for second pipeline candidate50% success